Finil Use In Pregnancy & Lactation

Use in Pregnancy: Pregnancy Risk Factor: D.
Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Dis­continue as soon as possible once pregnancy is detected.
The use of drugs which act on the renin-angio­tensin system are associated with oligohydramnios. Oligo­hydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Use is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate.
The exposed fetus should be monitored for fetal growth, amniotic fluid volume, and organ formation. Infants exposed in utero should be monitored for hyperkalemia, hypotension, and oliguria (exchange transfusions or dialy­sis may be needed). These adverse events are generally associated with maternal use in the second and third trimesters.
Untreated chronic maternal hypertension is also associ­ated with adverse events in the fetus, infant, and mother. The use of angiotensin II receptor blockers is not recommended to treat chronic uncomplicated hypertension in pregnant women and should generally be avoided in women of reproductive potential.
Use in Lactation: It is not known if can­desartan is excreted into breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.